Brainstorm Cell Therapeutics Inc. (BCLI)
Symbol Info
Listed Symbol BCLI
Name Brainstorm Cell Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-0.70
Price Info
21 Day Moving Average $3.9038
21 Day EMA $3.905980
50 Day Moving Average $3.8537
50 Day EMA $3.897650
200 Day EMA $3.852720
200 Day Moving Average 3.870990
52 Week High $4.50
52 Week Low $2.92
52 Week Change $12.215899
Alpha 0.002775
Beta 1.2348
Standard Deviation 0.154224
R2 0.075605
Periods 60
Share Information
10 Day Average Volume 28,885
20 Day Average Volume 42,332
30 Day Average Volume 45,460
50 Day Average Volume 85,163
Outstanding Shares 22,550,442
Float Shares 18,458,294
Percent Float 81.85%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 55
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 286,857
Institute Holdings Percent 14.400000
Institute Sold Previous 3 Months 347,193
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 3
Insider Holdings Percent 19.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,092,148
Price Change
7 Day Price Change $0.0800002
7 Day Percent Change 2.07%
21 Day Price Change $0.0699999
21 Day Percent Change 1.80%
30 Day Price Change $-0.0800002
30 Day Percent Change -1.99%
Month To Date Price Change $0.0500
Month To Date Percent 1.28%
90 Day Price Change $-0.11
90 Day Percent Change -2.71%
Quarter To Date $0.050000
Quarter To Date Percent 1.28%
180 Day Price Change $0.160000
180 Day Percent Change 4.22%
200 Day Price Change $-0.35
200 Day Percent Change -8.14%
Year To Date $0.400000
Year To Date Percent 11.27%
Profile
Description Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is a developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Details
Issue Type CS
Market Cap $89,074,246
Sec Type EQS
Auditor Brightman Almagor Zohar & Co.
Total Shares Outstanding 22,550,442
CEO Chaim Lebovits
Employees 32
Last Audit UE
Classification
CIK 0001137883
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1325 Avenue of Americas
28th Floor
New York, NY 10019
Website https://www.brainstorm-cell.com
Facisimile +1 201 430-7555
Telephone +1 201 488-0460
Email mrice@lifesciadvisors.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $88,082,723
Price To Sales -
Price To Free Cash -10.5
PE High Last 5 Years -
Price To Book 267.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -19
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 0.5
Leverage Ratio -2
Quick Ratio 0.4
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -123.72
Return On Equity -442.41
Return On Capital -263.5
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
BCLI
Brainstorm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.